Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Total metabolic tumor volume as a prognostic biomarker in high-burden follicular lymphoma: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJuhi ChovatiyaSVSaai Poornima VommiAJAkhil Jain

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis reveals total metabolic tumor volume predicts progression-free survival in high-burden follicular lymphoma, highlighting its integration with clinical risk scores.

Key Points

  • High total metabolic tumor volume correlates significantly with inferior progression-free survival and overall survival outcomes.
  • In eleven studies involving 2,631 patients, high TMTV yielded a pooled HR of 1.91 for PFS and 1.78 for OS, indicating poor prognosis.
  • Analysis through systematic review and meta-analysis showed TMTV is an independent prognostic biomarker for high-burden follicular lymphoma.
  • Integrating TMTV with β2-microglobulin enhances risk stratification, aiding clinical decision-making and treatment strategies.

Cite This Study

Chovatiya et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d710https://doi.org/10.1182/blood-2025-7127
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial2025
  2. 2Prognosis prediction beyond MTV using easy to calculate parameters derived from FDG-PET/CT, a pilot Study2025
  3. 3Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.02025
  4. 4Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy2025
  5. 5Role of Novel PET-CT Metabolic Measures Total Lesion Glycolysis (TLG) and Total Metabolic Tumor Volume (TMTV) in Prediction of Treatment Response in Hodgkin and Non-Hodgkin Lymphoma Patients2025